This finding was also observed in the studies by Driver et al. [6] and Wang et al. [46], which compared the probabilities of PFS between 14 meningioma patients with heterozygous CDKN2A/B deletions and 24 patients with homozygous CDKN2A/B deletions. This evidence concerns the gene CDKN2A and meningioma.